WASHINGTON: Consistent with its “America First” approach, the United States, the top global hotspot for coronavirus pandemic, has cornered virtually all the stocks for the next three months of Remdesivir, the drug that has been shown to mitigate effects of Covid-19.
Under terms of the deal, the US has secured more than 500,000 treatment courses of the drug for American hospitals through September. This represents 100 percent of the California-based drug-maker Gilead’s projected production for July (94,200 treatment courses), 90 percent of production in August (174,900 treatment courses), and 90 percent of production in September (232,800 treatment courses), leaving very little for rest of the world for the next three months.
US officials made no effort to conceal their satisfaction, even boasting of Washington’s success in snagging the medication for Americans as Europeans and rest of the world fumed